EyePoint Pharmaceuticals Inc (EYPT)
11.88
-0.18
(-1.49%)
USD |
NASDAQ |
Nov 04, 13:15
EyePoint Pharmaceuticals Revenue (Quarterly): 9.477M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 9.477M |
| March 31, 2024 | 11.68M |
| December 31, 2023 | 14.03M |
| September 30, 2023 | 15.20M |
| June 30, 2023 | 9.105M |
| March 31, 2023 | 7.683M |
| December 31, 2022 | 10.53M |
| September 30, 2022 | 10.01M |
| June 30, 2022 | 11.56M |
| March 31, 2022 | 9.294M |
| December 31, 2021 | 11.54M |
| September 30, 2021 | 9.059M |
| June 30, 2021 | 9.013M |
| March 31, 2021 | 7.323M |
| December 31, 2020 | 7.131M |
| September 30, 2020 | 15.70M |
| June 30, 2020 | 4.122M |
| March 31, 2020 | 7.489M |
| December 31, 2019 | 8.633M |
| September 30, 2019 | 2.509M |
| June 30, 2019 | 7.21M |
| March 31, 2019 | 2.012M |
| September 30, 2018 | 0.486M |
| June 30, 2018 | 0.715M |
| March 31, 2018 | 0.928M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.933M |
| September 30, 2017 | 0.385M |
| June 30, 2017 | 0.701M |
| March 31, 2017 | 0.59M |
| December 31, 2016 | 5.971M |
| September 30, 2016 | 0.277M |
| June 30, 2016 | 0.304M |
| March 31, 2016 | 0.324M |
| December 31, 2015 | 0.526M |
| September 30, 2015 | 0.466M |
| June 30, 2015 | 0.409M |
| March 31, 2015 | 0.328M |
| December 31, 2014 | 0.521M |
| September 30, 2014 | 25.31M |
| June 30, 2014 | 0.292M |
| March 31, 2014 | 1.992M |
| December 31, 2013 | 0.592M |
| September 30, 2013 | 0.597M |
| June 30, 2013 | 0.492M |
| March 31, 2013 | 0.513M |
| December 31, 2012 | 0.585M |
| September 30, 2012 | 0.553M |
| June 30, 2012 | 0.699M |
| March 31, 2012 | 0.538M |
| December 31, 2011 | 0.63M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.122M
Minimum
Jun 2020
15.70M
Maximum
Sep 2020
9.926M
Average
9.294M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Cassava Sciences Inc | -- |
| Adverum Biotechnologies Inc | -- |
| Regenxbio Inc | 22.30M |
| Editas Medicine Inc | 0.513M |
| Apellis Pharmaceuticals Inc | 199.68M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -30.83M |
| Total Expenses (Quarterly) | 44.02M |
| EPS Diluted (Quarterly) | -0.58 |
| Enterprise Value | 365.18M |
| Gross Profit Margin (Quarterly) | 85.22% |
| Profit Margin (Quarterly) | -325.3% |
| Earnings Yield | -14.98% |
| Normalized Earnings Yield | -14.98 |